Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study

M Rudwaleit, E Rødevand, P Holck, J Vanhoof, M Kron, S Kary, H Kupper, M Rudwaleit, E Rødevand, P Holck, J Vanhoof, M Kron, S Kary, H Kupper

Abstract

Objective: To evaluate the effect of adalimumab on the frequency of anterior uveitis (AU) flares in patients with active ankylosing spondylitis (AS).

Methods: We determined the history of ophthalmologist-diagnosed AU in 1250 patients with active AS who were enrolled in a multinational, open-label, uncontrolled clinical study of treatment with adalimumab, 40 mg every other week for up to 20 weeks. All AU flares were documented throughout the adalimumab treatment period plus 70 days. We compared the rates of AU flares per 100 patient years (PYs) reported during the year before adalimumab treatment with rates during adalimumab treatment, in total and by patient subgroups.

Results: The AU flare rates before adalimumab treatment were 15/100 PYs in all patients (n = 1250), 68.4/100 PYs in 274 patients with a history of AU flares, 176.9/100 PYs in 106 patients with a recent history of AU flares, 192.9/100 PYs in 28 patients with symptomatic AU at baseline and 129.1/100 PYs in 43 patients with a history of chronic uveitis. During adalimumab treatment, the rate of AU flares was reduced by 51% in all patients, by 58% in 274 patients with a history of AU, by 68% in 106 patients with a recent history of AU, by 50% in 28 patients with symptomatic AU at baseline and by 45% in 43 patients with chronic uveitis. AU flares during adalimumab treatment were predominantly mild. Two patients with periods of high AS disease activity had new-onset AU during the treatment period.

Conclusions: Results of this prospective open-label study suggest that adalimumab had a substantial preventive effect on AU flares in patients with active AS, including patients with a recent history of AU flares. Clinical trials: ClinicalTrials.gov Identifier: NCT00478660.

Conflict of interest statement

Competing interests: MR, ER, PH and JV were RHAPSODY study investigators. MK and HK are employees of Abbott GmbH & Co KG, an affiliate of Abbott Laboratories. They hold shares of Abbott stock. SK is a contractor of Abbott GmbH.

References

    1. Rosenbaum JT, Smith JR. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol 2002;20(Suppl 28):S143–5
    1. Hamideh F, Prete PE. Ophthalmologic manifestations of rheumatic diseases. Semin Arthritis Rheum 2001;30:217–41
    1. Pato E, Banares J, Jover JA, Fernandez-Gutierrez B, Godoy F, Morado C, et al. Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis. J Rheumatol 2000;27:2198–202
    1. Linder R, Hoffmann A, Brunner R. Prevalence of the spondylarthritides in patients with uveitis. J Rheumatol 2004;31:2226–9
    1. Monnet D, Breban M, Hudry C, Dougados M, Brézin AP. Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology 2004;111:802–9
    1. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509–16
    1. Benitez del Castillo JM, Garcia Sanchez J, Tradier T, Banares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 2000;14:340–3
    1. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-α therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002;109:2342–6
    1. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252–7
    1. Smith JA, Thompson DJS, Whitcup SM, Suhler E, Clarke G, Smith S, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18–23
    1. Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, et al. Tumour necrosis factor α inhibitors in the treatment of childhood uveitis. Rheumatology Oxford 2006;45:982–9
    1. Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 2006;33:231–7
    1. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006;113:860–4
    1. Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007;125:895–900
    1. Tynhälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548–50
    1. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;116:2317–23
    1. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447–51
    1. Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, et al. Efficacy of tumour necrosis factors blockers in reducing uveitis flares in spondyloarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631–4
    1. Tiliakos AN, Tiliakos NA. Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary? J Rheumatol 2003;30:2727.
    1. Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 2003;21:645–6
    1. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol 2003;87:925.
    1. Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121:437–40
    1. Monnet D, Moachon L, Dougados M, Brézin AP. Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis. Nat Clin Pract Rheumatol 2006;2:393–7
    1. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248–52
    1. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8
    1. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91
    1. Rudwaleit M, Claudepierre P, Wordsworth P, Loza E, Wong R, Kron M, et al. Predictors of major clinical responses (BASDAI50, ASAS40, ASAS partial remission) in 1,250 patients treated with adalimumab (HUMIRA) for active ankylosing spondylitis. Ann Rheum Dis 2008;67(Suppl 2):516
    1. Braun J, van der Heijde D, Dougados M, Emery P, Khan MA, Sieper J, et al. Staging of patients with ankylosing spondylitis: a preliminary proposal. Ann Rheum Dis 2002;61(Suppl 3):19–23
    1. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876–86
    1. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNFα treatment. Ann Rheum Dis 2004;63:1438–44
    1. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817–24
    1. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D, ASAS Working Group First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316–20
    1. Di Gangi M, Foti R, Leonardi R, Leonetti C, Castellino P. Recurrent new-onset uveitis in a patient with rheumatoid arthritis during anti-TNFα treatment. Reumatismo 2007;59:169–72
    1. Kaipiainen-Seppänen O, Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor α inhibitors. Ann Rheum Dis 2003;62:88–9
    1. Coates LC, McGonagle DG, Bennett AN, Emery P, Marzo-Ortega Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. Ann Rheum Dis 2008;67:729–30

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit